• Tomoyasu Ito, Akihito Nagahara, Taro Osada, Junko Kato, Hiroya Ueyama, Hiroaki Saito, Nobuhito Taniki, Ryo Kanazawa, Ryo Shimizu, Jinkan Sai, Shuichiro Shiina, and Sumio Watanabe.
• Department of Gastroenterology, School of Medicine, Juntendo University, Tokyo 113-8421, Japan.
• Biomed Rep. 2015 Jul 1; 3 (4): 457-460.

AbstractRecombinant human soluble thrombomodulin (rTM) was approved recently and has been used for treatment of disseminated intravascular coagulation (DIC). The aim of the present study was to evaluate the efficacy of rTM for DIC. The data of 53 inpatients with sepsis-induced DIC were retrospectively analyzed. Patients were classified into the rTM treatment group (n=25) and conventional treatment group (rTM not used) was the control group (n=28). Diagnosis of DIC was made according to the criteria for acute DIC of the Japan Association of Acute Medicine. Platelet count, prothrombin time-international normalized ratio, levels of fibrin/fibrinogen degradation products (FDP), C-reactive protein and DIC scores were measured on days 0, 3 and 7. Furthermore, the DIC resolution rate was assessed on days 3 and 7. Prior to treatment, DIC scores were 5.0±1.0 in the rTM group and 5.9±1.3 in the control group (P<0.05). Significant intra-group improvements were observed in all the parameters, except for FDP in the two groups. Significant improvements were observed in the DIC scores in the rTM group (Δ2.0±1.9 vs. Δ1.5±1.9, P=0.001). Therefore, the results suggest that rTM would be a useful medicine for treatment of DIC in the gastroenterology field.

5 keywords...

hide…